Integra LifeSciences [IART] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Integra LifeSciences
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Integra LifeSciences wins in 4 metrics, Abbott Laboratories wins in 15 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Integra LifeSciences | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.48 | 16.78 | Abbott Laboratories |
| Price-to-Book Ratio | 1.13 | 4.60 | Integra LifeSciences |
| Debt-to-Equity Ratio | 194.07 | 26.50 | Abbott Laboratories |
| PEG Ratio | 5.98 | 0.46 | Abbott Laboratories |
| EV/EBITDA | 9.60 | 20.89 | Integra LifeSciences |
| Profit Margin (TTM) | -30.87% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 7.86% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | 7.86% | 19.73% | Abbott Laboratories |
| Return on Equity | -38.92% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 2.43% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $15.01M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -13.80% | 14.93% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 0.72 | 5.40 | Integra LifeSciences |
| Enterprise Value | $2.94B | $239.20B | Abbott Laboratories |
| EV/Revenue Ratio | 1.81 | 5.55 | Integra LifeSciences |
| Gross Profit Margin (TTM) | 50.37% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $21 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-6.54 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.20 | 0.69 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Integra LifeSciences vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -2.65% | -5.82% | 9.37% | 18.68% | -32.28% | -34.58% |
| Abbott Laboratories | 0.81% | 0.59% | 2.07% | -1.99% | 2.65% | 17.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -13.80% | -66.94% | -67.70% | -53.11% | -22.41% | -17.25% |
| Abbott Laboratories | 14.93% | 28.63% | 25.19% | 208.75% | 439.87% | 537.35% |
News Based Sentiment: Integra LifeSciences vs Abbott Laboratories
Integra LifeSciences
News based Sentiment: MIXED
The month presented a mixed bag for Integra LifeSciences, with a stock price decline and negative price prediction offset by a clear growth strategy for 2026 and ongoing operational improvements. Analyst sentiment remains cautious, reflecting the ongoing challenges and uncertainties surrounding the company's turnaround.
Abbott Laboratories
News based Sentiment: MIXED
September presented a mixed bag for Abbott, with positive developments in diabetes technology and solid earnings offset by a lowered revenue forecast due to challenges in China. While the company continues to innovate and expand its reach, the near-term headwinds create uncertainty for investors, making this a moderately significant month.
Performance & Financial Health Analysis: Integra LifeSciences vs Abbott Laboratories
| Metric | IART | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.17B | $232.75B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 1,202,480 | 5,176,450 |
| 90 Day Avg. Volume | 1,384,253 | 5,323,787 |
| Last Close | $15.06 | $133.73 |
| 52 Week Range | $11.06 - $27.13 | $110.86 - $141.23 |
| % from 52W High | -44.49% | -5.31% |
| All-Time High | $77.40 (Apr 26, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -80.54% | -6.22% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.07% |
| Quarterly Earnings Growth | -0.01% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.31% | 0.32% |
| Operating Margin (TTM) | 0.08% | 0.20% |
| Return on Equity (TTM) | -0.39% | 0.31% |
| Debt to Equity (MRQ) | 194.07 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.33 | $29.05 |
| Cash per Share (MRQ) | $3.26 | $4.18 |
| Operating Cash Flow (TTM) | $70.89M | $9.04B |
| Levered Free Cash Flow (TTM) | $45.35M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Integra LifeSciences vs Abbott Laboratories
| Metric | IART | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.48 | 16.78 |
| Forward P/E | 5.98 | 25.92 |
| PEG Ratio | 5.98 | 0.46 |
| Price to Sales (TTM) | 0.72 | 5.40 |
| Price to Book (MRQ) | 1.13 | 4.60 |
| Market Capitalization | ||
| Market Capitalization | $1.17B | $232.75B |
| Enterprise Value | $2.94B | $239.20B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.81 | 5.55 |
| Enterprise to EBITDA | 9.60 | 20.89 |
| Risk & Other Metrics | ||
| Beta | 1.20 | 0.69 |
| Book Value per Share (MRQ) | $13.33 | $29.05 |
Financial Statements Comparison: Integra LifeSciences vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IART | ABT |
|---|---|---|
| Revenue/Sales | $415.61M | $10.36B |
| Cost of Goods Sold | $206.27M | $4.47B |
| Gross Profit | $209.33M | $5.89B |
| Research & Development | $27.00M | $716.00M |
| Operating Income (EBIT) | $-1.31M | $1.69B |
| EBITDA | $39.15M | $2.66B |
| Pre-Tax Income | $-530.95M | $1.78B |
| Income Tax | $-46.88M | $453.00M |
| Net Income (Profit) | $-484.07M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IART | ABT |
|---|---|---|
| Cash & Equivalents | $239.10M | $6.53B |
| Total Current Assets | $1.11B | $23.15B |
| Total Current Liabilities | $918.45M | $13.00B |
| Long-Term Debt | $1.39B | $12.74B |
| Total Shareholders Equity | $1.52B | $49.06B |
| Retained Earnings | $914.62M | $47.72B |
| Property, Plant & Equipment | $561.38M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IART | ABT |
|---|---|---|
| Operating Cash Flow | $5.80M | $1.42B |
| Capital Expenditures | $-28.92M | $-484.00M |
| Free Cash Flow | $-40.18M | $933.00M |
| Debt Repayment | $-15.24M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | IART | ABT |
|---|---|---|
| Shares Short | 7.19M | 17.75M |
| Short Ratio | 4.79 | 3.27 |
| Short % of Float | 0.15% | 0.01% |
| Average Daily Volume (10 Day) | 1,202,480 | 5,176,450 |
| Average Daily Volume (90 Day) | 1,384,253 | 5,323,787 |
| Shares Outstanding | 77.16M | 1.73B |
| Float Shares | 59.27M | 1.73B |
| % Held by Insiders | 0.14% | 0.01% |
| % Held by Institutions | 0.95% | 0.81% |
Dividend Analysis & Yield Comparison: Integra LifeSciences vs Abbott Laboratories
| Metric | IART | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |